SCHEMBL5688267

SCHEMBL5688267

Cc1ccc(Oc2ccc(OCC3CCN(C(=O)Oc4ccc(N5C(=O)C6CCCCC6C5=O)cn4)CC3)cc2)nc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 9/20 0.45
ACACB O00763 1/20 0.39
BCHE P06276 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRIN2B Q13224 1/20 0.37
GPR119 Q8TDV5 4/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5688056 0.89 LIPE (0.45) LIPEACACBBCHEKMT2AL3MBTL1
SCHEMBL5687360 0.89 LIPE (0.42) LIPEACACBBCHEKMT2AL3MBTL1
SCHEMBL5687328 0.86 KMT2A (0.42) LIPEKMT2AL3MBTL1ALDH1A1POLB
SCHEMBL5931957 0.86 LIPE (0.44) LIPEACACBBCHEGRIN2BGPR119
SCHEMBL5689609 0.84 KMT2A (0.47) LIPEACACBKMT2AL3MBTL1ALDH1A1
SCHEMBL5714870 0.81 HRH3 (0.46) KMT2AALDH1A1LMNAPOLBMAPT
SCHEMBL5687518 0.79 LIPE (0.54) LIPEBCHEGRIN2B
SCHEMBL5715004 0.79 ALDH1A1 (0.38) KMT2AL3MBTL1ALDH1A1LMNAPOLB
SCHEMBL5688198 0.79 LIPE (0.46) LIPEACACBPOLBGRIN2BCYP4F2
SCHEMBL5931494 0.78 LIPE (0.51) LIPEACACBBCHEGRIN2BCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC LIPE 1/4885ACACB 180/4885BCHE 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.